

Haematologica
HAEMATOL/2017/181404
Version 3

Emergence and evolution of TP53 mutations are a key feature of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Laurence Lodé, Audrey Ménard, Laurent Flet, Steven Richebourg, Marion Loirat, Marion Eveillard, Yannick Le Bris, Catherine Godon, Olivier Theisen, Anne-Laure Gagez, Guillaume Cartron, Thérèse Commes-Maerten, Bruno Villemagne, Odile Luycx, Pascal Godmer, Catherine Pellat-Deceunynck, Thierry Soussi, Marie C Béné, Jacques Delaunay, and Pierre Peterlin

Disclosures: No COI to disclose

Contributions: Authorship contributions Conception and design: Laurence Lodé, Jacques Delaunay Provision of study material or patients: Steven Richebourg, Jacques Delaunay, Pierre Peterlin, Bruno Villemagne, Odile Luycx. Collection and assembly of data: Laurence Lodé, Audrey Ménard, Steven Richebourg, Yannick Le Bris, Jacques Delaunay, Pierre Peterlin, Marion Eveillard, Marion Loirat, Catherine Godon, Olivier Theisen, Anne-Laure Gagez, Marie C Béné, Laurent Flet Data analysis and interpretation: Laurence Lodé, Audrey Ménard, Thierry Soussi, Jacques Delaunay, Pierre Peterlin Manuscript writing: Laurence Lodé, Audrey Ménard, Jacques Delaunay, Marie C Béné Critical review of the paper: Pierre Peterlin, Yannick Le Bris, Marie C Béné, Thérèse Commes-Maerten, Guillaume Cartron, Catherine Pellat Deceunynck Final approval of manuscript: All authors